BALL:NYSEBall Corporation Analysis
Data as of 2026-05-23 - not real-time
$56.51
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Ball Corporation delivered a strong Q1 2026, posting revenue of $3.6 billion, a 16.3% year‑over‑year increase. Non‑GAAP EPS came in at $0.94, topping consensus estimates by 11.3%. The company also announced a quarterly dividend of $0.80, yielding about 1.42% with a modest 23% payout ratio. On the price side, the stock trades at $56.51, comfortably above the computed support level of $54.58. Technical gauges show a neutral trend, an RSI of 40.8 indicating slight undervaluation, and a bearish MACD histogram of –0.10. Volume has been on a decreasing trajectory, suggesting reduced short‑term buying pressure.
Analysts assign a “Buy” consensus with a median price target of $71.5, implying roughly 25% upside from current levels. The consensus fair‑value estimate of $70.86 aligns with that upside and places the stock in the undervalued category relative to market price. A low computed beta of 0.40 and a 30‑day volatility of 29.9% point to modest systematic risk but notable price swings. The dividend appears sustainable given a 23% payout and solid operating cash flow of $1.15 billion. Sector‑specific risks are moderate, while regulatory and geographic exposures remain medium. Overall, the combination of earnings momentum, attractive valuation and defensive dividend profile supports a buy stance across horizons.
Analysts assign a “Buy” consensus with a median price target of $71.5, implying roughly 25% upside from current levels. The consensus fair‑value estimate of $70.86 aligns with that upside and places the stock in the undervalued category relative to market price. A low computed beta of 0.40 and a 30‑day volatility of 29.9% point to modest systematic risk but notable price swings. The dividend appears sustainable given a 23% payout and solid operating cash flow of $1.15 billion. Sector‑specific risks are moderate, while regulatory and geographic exposures remain medium. Overall, the combination of earnings momentum, attractive valuation and defensive dividend profile supports a buy stance across horizons.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Q1 earnings beat
- price near support
- decreasing volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- analyst upside potential
- robust revenue growth
- sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- low beta and defensive profile
- stable operating cash flow
- strong industry positioning
Key Metrics & Analysis
Financial Health
Revenue Growth16.30%
Profit Margin6.86%
P/E Ratio16.5
ROE16.79%
ROA4.70%
Debt/Equity145.54
P/B Ratio2.7
Op. Cash Flow$1.1B
Free Cash Flow$403.5M
Technical Analysis
TrendNeutral
RSI40.8
Support$54.58
Resistance$62.35
MA 20$58.17
MA 50$59.97
MA 200$55.17
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61
Valuation
Fair Value$10.73
Target Price$70.79
Upside/Downside25.26%
GradeUndervalued
TypeBlend
Dividend Yield1.42%
Risk Assessment
Beta0.40
Volatility29.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.